Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	214.33	163.89	71.41	83.08	39.48
Depreciation & Amortization	37.87	37.77	32.88	1.24	0.19
Stock-Based Compensation	24.78	22.25	14.25	7.91	6.07
Other Adjustments	-7.41	-15.02	62.38	10.09	9.6
Change in Receivables	-61	-11.96	-43.08	-3.82	-0.63
Changes in Inventories	-18.09	-3.9	-4.74	1.07	-3.22
Changes in Accounts Payable	-5.39	1.8	10.82	1.21	-1.49
Changes in Accrued Expenses	24.16	53.85	5.8	16.39	5.52
Changes in Other Operating Activities	-0.58	-8.87	-6.13	-1.11	4.84
Operating Cash Flow	208.67	239.81	143.6	116.05	60.37
Operating Cash Flow Growth	-12.98%	67.00%	23.74%	92.22%	34.06%
Capital Expenditures	-0.06	-0.56	-0.23	-0.03	-1.02
Purchases of Intangible Assets	-	-	-81.51	-	-
Purchases of Investments	-	-	-13.47	-	-10
Proceeds from Sale of Investments	-	-	-	19.24	-
Payments for Business Acquisitions	-	-	-198.29	-10	-
Investing Cash Flow	-0.06	-0.56	-293.5	9.21	-11.02
Issuance of Common Stock	14.67	154.52	2.79	9.57	4.1
Repurchase of Common Stock	-27.07	-0.67	-0.98	-7.14	-12.24
Net Common Stock Issued (Repurchased)	-12.4	153.85	1.81	2.43	-8.14
Other Financing Activities	-4.59	-13.18	-12.67	-0.74	-
Financing Cash Flow	-16.99	140.67	-10.86	1.69	-8.14
Net Cash Flow	191.62	379.92	-160.76	126.95	41.21
Free Cash Flow	208.61	239.25	143.37	116.02	59.35
Free Cash Flow Growth	-12.81%	66.88%	23.57%	95.48%	31.82%
FCF Margin	35.42%	48.65%	36.00%	54.16%	42.14%
Free Cash Flow Per Share	1.64	1.91	1.26	1.04	0.55
Levered Free Cash Flow	252.25	243.98	109.81	101.84	44.31
Unlevered Free Cash Flow	232.79	227.96	103.99	99.55	44.1

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q